[{"from": "human", "value": "Describe this molecule. [C][N][C][=Branch1][C][=O][C][=C][Branch2][Ring2][=Branch2][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][C][=N][N][C][=Branch1][#Branch2][=C][N][=C][Ring1][Branch1][N][=C][Ring1][=Branch2][C][C][=C][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][N][=C][C][=C][Ring1][Branch2][F]"}, {"from": "gpt", "value": "The molecule is an orally bioavailable inhibitor of the proto-oncogene c-Met (also known as hepatocyte growth factor receptor (HGFR)) with potential antineoplastic activity. Capmatinib selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis."}]